Gilead, Teva Defeat $3.6B HIV Drug Antitrust Case At Trial

By Bonnie Eslinger · June 30, 2023, 4:56 PM EDT

A California federal jury cleared Gilead and Teva on Friday in a $3.6 billion antitrust case claiming the pharmaceutical giants struck an illegal "pay-for-delay" patent deal that inflated prices for two HIV...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

3:19-cv-02573

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019